- Home
- AGIO vs ENHA Comparison
AGIO vs ENHA Comparison
Compare AGIO & ENHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGIO | ENHA |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | AGIO | ENHA |
|---|---|---|
| Price | $35.65 | $4.07 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $38.88 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 608.7K |
| Earning Date | 04-29-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $43,011,000.00 | N/A |
| Revenue This Year | $76.75 | N/A |
| Revenue Next Year | $170.73 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.24 | $3.98 |
| 52 Week High | $46.00 | $4.60 |
Technical Indicators
Market Signals| Indicator | AGIO | ENHA |
|---|---|---|
| Relative Strength Index (RSI) | 74.22 | N/A |
| Support Level | $26.71 | N/A |
| Resistance Level | $36.07 | N/A |
| Average True Range (ATR) | 1.44 | 0.00 |
| MACD | 0.79 | 0.00 |
| Stochastic Oscillator | 98.76 | 0.00 |
Price Performance
Historical ComparisonAbout AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.